Eli Lilly news covering GLP-1 drugs Mounjaro and Zepbound, obesity and diabetes pipeline, earnings, and Lilly's race with Novo Nordisk.
Eli Lilly acquired AtaiBeckley for up to $3.8 billion, gaining BPL-003, a psychedelic nasal spray for treatment-resistant depression. The deal follows the merger of Beckley Psytech and atai Life Sciences in November 2025. Initial Phase 3 results are expected in 2029.
UBS analyst Michael Yee raised Eli Lilly's price target to $1,425 from $1,250, implying 20% upside, citing strong sales of Mounjaro and Zepbound and optimism around Alzheimer's drug Kisunla.
This commentary argues that Eli Lilly's acquisition of AtaiBeckley signals growing interest in psychedelic therapies, while UnitedHealth's earnings beat reflects strength in healthcare. It suggests General Electric's raised outlook indicates robust travel demand, framing these as key market movers.